The FDA has granted accelerated approval to Merus’s zenocutuzumab (Bizengri) for pancreatic adenocarcinomas and non-small-cell lung cancers (NSCLC) carrying NRG1 gene fusions. Zenocutuzumab is ...

The FDA has approved Jazz Pharmaceuticals and Zymeworks’s HER2 × HER2 bispecific antibody, for HER2-positive biliary tract cancer (BTC). The antibody, called zanidatamab (Ziihera), validates ...

Center for Drug Evaluation (CDE) has approved Alphamab Oncology’s investigational new drug application (IND) for the ...

JSKN033-102 is an open-label, multicenter, Phase Ⅰ/Ⅱ clinical study designed to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and anti-tumor activity of JSKN033 in patients with ...

Panelist discusses how there are many significant attributes of the bispecific antibody, which has broader applicability and can be used in widespread community centers. There are more community ...

Jazz Pharmaceuticals announced that the FDA has approved ZIIHERA® (zanidatamab-hrii) on an accelerated basis for the treatment ...

FDA has granted accelerated approval to Bizengri® (zenocutuzumab-zbco), a first-in-class bispecific antibody targeting NRG1+ ...

Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on ALX Oncology Holdings (ALXO – Research Report) and keeping the ...

Zanidatamab is an HER2-targeted bispecific antibody with multiple novel mechanisms of action that has demonstrated ‘compelling’ anti-tumour activity in several HER2-expressing cancers ...

MI Cancer Seek, a companion diagnostic, combines exome and transcriptome sequencing to guide targeted therapy decisions for various cancers. Ziihera, a dual HER2-targeted bispecific antibody, ...